In March 2024 Croda and The Access to Advanced Health Institute (AAHI) announced the signing of a partnership agreement on innovation and development of adjuvant formulations. The agreement will allow the organisations to “leverage their combined expertise” to make novel vaccine adjuvant formulations “globally accessible”. This will facilitate the development of “next generation, robust, and durable vaccines”.
AAHI meets Croda
AAHI is described as a “leading nonprofit biotech research institute” that has developed platform technologies to harness the immune system against disease. It “boasts a diverse portfolio of adjuvant formulations”, which are used in “numerous vaccine candidates”.
“With deep adjuvant and vaccine formulation expertise and years of experience developing cost-effective, sustainable products and processes for making them, AAHI stands at the forefront of vaccine innovation.”
Croda was “founded on the principle of using smart science to turn bio-based raw materials into innovative ingredients that help to improve lives”.
“We envision a future where everyone gets the vaccines they need. This reality relies on maintaining vaccines access and continuing to innovate in this realm. The responsibility is on us all to not only select sustainable ingredients, but to secure supply chains and sources that will not deplete in the future.”
The exclusive agreement between the two organisations includes a “collaborative effort in research and development” to “propel rapid development of innovative adjuvants and formulations” and to develop “efficient manufacturing processes to enable production at scale, to meet vaccine industry and global needs”. Croda is to apply its “unparalleled cGMP manufacturing expertise” to scale up manufacturing and support for Phase III clinical trials and commercial use.
The vaccines of tomorrow
President Life Sciences at Croda is Daniele Piergentili, who commented that the partnership represents “another significant milestone” in the team’s “endeavour to offer a comprehensive portfolio of adjuvants for the vaccines of tomorrow”.
“It perfectly aligns with our pharmaceutical strategy to ‘Empower biologics delivery’ and underscores our commitment to making substantial contributions to the successful development and commercialisation of WHO-listed pipeline vaccines.”
Dr Corey Casper, President and Chief Executive Officer of AAHI, identifies “tremendous” opportunities for AAHI and “collaborators and vaccine developers who rely on adjuvant formulations for the deployment of effective health solutions”.
“Croda’s commitment to and passion for developing sustainable adjuvant formulation solutions from bench to clinic to market is in direct alignment with our mission to create worldwide access to vaccines and immunotherapies.”
We look forward to welcoming representatives from both Croda and AAHI to the Congress in Washington this April; are you joining us there? If you can’t make it, why not subscribe for more insights here!
